PharmaEssentia Corporation (6446.TW)

TWD 573.0

(1.24%)

EBITDA Summary of PharmaEssentia Corporation

  • PharmaEssentia Corporation's latest annual EBITDA in 2023 was -671.48 Million TWD , up 57.91% from previous year.
  • PharmaEssentia Corporation's latest quarterly EBITDA in 2024 Q2 was 1.02 Billion TWD , up 956.18% from previous quarter.
  • PharmaEssentia Corporation reported an annual EBITDA of -1.59 Billion TWD in 2022, up 38.02% from previous year.
  • PharmaEssentia Corporation reported an annual EBITDA of -2.57 Billion TWD in 2021, down -45.83% from previous year.
  • PharmaEssentia Corporation reported a quarterly EBITDA of 1.02 Billion TWD for 2024 Q2, up 956.18% from previous quarter.
  • PharmaEssentia Corporation reported a quarterly EBITDA of -129.5 Million TWD for 2023 Q2, up 81.23% from previous quarter.

Annual EBITDA Chart of PharmaEssentia Corporation (2023 - 2019)

Historical Annual EBITDA of PharmaEssentia Corporation (2023 - 2019)

Year EBITDA EBITDA Growth
2023 -671.48 Million TWD 57.91%
2022 -1.59 Billion TWD 38.02%
2021 -2.57 Billion TWD -45.83%
2020 -1.76 Billion TWD -127.65%
2019 -775.31 Million TWD 0.0%

Peer EBITDA Comparison of PharmaEssentia Corporation

Name EBITDA EBITDA Difference
Grape King Bio Ltd 2.88 Billion TWD 123.275%
Standard Chem & Pharm CO., LTD. 1.57 Billion TWD 142.527%
Maywufa Company Ltd. 239.81 Million TWD 380.003%
ScinoPharm Taiwan, Ltd. 819.15 Million TWD 181.973%
Lotus Pharmaceutical Co., Ltd. 6.87 Billion TWD 109.773%
LIWANLI Innovation Co., Ltd. 6.81 Million TWD 9960.294%
YungShin Global Holding Corporation 1.35 Billion TWD 149.47%
PhytoHealth Corporation -20.69 Million TWD -3144.207%
SCI Pharmtech, Inc. 529.61 Million TWD 226.788%
Formosa Laboratories, Inc. 1.16 Billion TWD 157.722%
Bora Pharmaceuticals Co., LTD. 5.73 Billion TWD 111.71%